Superluminal Medicines
Rapid discovery of small molecule therapeutics
CORE INFO
Superluminal Medicines is a biotechnology company that leverages its proprietary Hyperloop™ Platform to rapidly discover and develop small molecule therapeutics, primarily targeting G protein-coupled receptors (GPCRs) for treating cardiometabolic diseases and obesity.
- Superluminal Medicines raised $120 million in a Series A round in September 2024, led by RA Capital Management, with participation from Eli Lilly and Company, NVentures, and others.cen.acs.org
- The company entered a collaboration with Eli Lilly and Company, potentially worth up to $1.3 billion, to develop small molecule therapeutics for cardiometabolic diseases and obesity.superluminalrx.com
- Reuters reported on the $1.3 billion deal between Eli Lilly and Superluminal Medicines to discover obesity medicines using AI.investing.com
WHY WE WOULD WORK AT SUPERLUMINAL MEDICINES
Innovative Drug Discovery
Join a team revolutionizing small molecule therapeutics with the Hyperloop™ Platform, integrating AI and structure-based drug discovery to accelerate the development of life-changing medicines.
Focus on Patient Needs
Contribute to addressing critical unmet patient needs in cardiometabolic diseases and obesity, ensuring that compassion drives every aspect of your work.
Strong Financial Backing
Be part of a rapidly growing company that has raised $158 million in funding, including a significant collaboration with Eli Lilly potentially worth $1.3 billion.
Collaborative Culture
Work alongside a passionate team of scientists and innovators who value diverse perspectives and foster a collaborative environment to tackle complex challenges.
Cutting-Edge Technology
Utilize advanced AI and big data infrastructure to model protein shapes and design selective compounds, pushing the boundaries of what's possible in drug discovery.
Rapid Growth Opportunities
Experience rapid career advancement in a dynamic startup environment, where your contributions directly impact the future of medicine and the company's success.
MARKET AND TRACTION
TOTAL ADDRESSABLE MARKET
KEY METRICS
✦ KEY METRICNOTABLE CUSTOMERS
GROWTH TACTICS
COMPETITIVE ADVANTAGE
PRODUCT AND TECH
Hyperloop™ Platform
Superluminal Medicines' proprietary Hyperloop™ Platform integrates structure-based drug discovery with artificial intelligence and experimental validation, enabling the rapid identification and development of candidate-ready small molecule therapeutics.
G Protein-Coupled Receptor Targeting
The company focuses on targeting G protein-coupled receptors (GPCRs), which are crucial for developing innovative treatments for cardiometabolic diseases and obesity, addressing significant unmet patient needs.
AI-Powered Drug Discovery
Utilizing advanced AI algorithms, Superluminal Medicines enhances the drug discovery process by modeling protein structures and designing highly selective compounds, significantly accelerating the timeline for therapeutic development.
Experimental Validation Techniques
Superluminal employs rigorous experimental validation methods to confirm the efficacy and safety of its candidate compounds, ensuring that only the most promising therapeutics advance to clinical trials.
Collaborative Development Agreements
The company has established strategic collaborations, such as its notable partnership with Eli Lilly and Company, to leverage shared expertise and resources in developing small molecule therapeutics.